摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-乙基-4-甲基喹啉-2(1H)-酮 | 51592-38-2

中文名称
6-乙基-4-甲基喹啉-2(1H)-酮
中文别名
6-乙基-4-甲基-2(1H)-喹啉酮;6-乙基-4-甲基-1H-喹啉-2-酮;6-乙基-4-甲基-喹诺酮
英文名称
6-ethyl-4-methyl-1H-quinolin-2-one
英文别名
6-ethyl-4-methyl-2(1H)-quinolinone;6-ethyl-4-methyl-1H-quinolin-2-one
6-乙基-4-甲基喹啉-2(1H)-酮化学式
CAS
51592-38-2
化学式
C12H13NO
mdl
MFCD10000799
分子量
187.241
InChiKey
JFYWBUOEUUZAEX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933790090

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-乙基-4-甲基喹啉-2(1H)-酮sodium hydroxide三氯氧磷 作用下, 以77%的产率得到2-氯-6-乙基-4-甲基喹啉
    参考文献:
    名称:
    Compounds for the treatment of pain
    摘要:
    这项发明提供了治疗疼痛、尿失禁和其他由NPFF受体介导的异常的方法,包括向受试者施用在NPFF1受体、NPFF2受体或同时在NPFF1和NPFF2受体上起作用的化学化合物的治疗有效量。
    公开号:
    US20030176314A1
  • 作为产物:
    描述:
    N-(4-乙基苯基)-3-氧代丁酰胺硫酸 作用下, 以 甲醇 为溶剂, 以66%的产率得到6-乙基-4-甲基喹啉-2(1H)-酮
    参考文献:
    名称:
    Compounds for the treatment of pain
    摘要:
    这项发明提供了治疗疼痛、尿失禁和其他由NPFF受体介导的异常的方法,包括向受试者施用在NPFF1受体、NPFF2受体或同时在NPFF1和NPFF2受体上起作用的化学化合物的治疗有效量。
    公开号:
    US20030176314A1
点击查看最新优质反应信息

文献信息

  • ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS
    申请人:Pinto Donald J.P.
    公开号:US20100016316A1
    公开(公告)日:2010-01-21
    The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L 1 , R 3 , R 4 , R 8a , R 11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    本发明提供了化合物的结构式(I)或(II): 或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式,其中变量A、L1、R3、R4、R8a、R11和M如本文所定义。结构式(I)或(II)的化合物是凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂;例如凝血酶、Xa因子、XIa因子、IXa因子、VIIa因子和/或血浆激肽。具体而言,涉及选择性XIa因子抑制剂或fXIa和血浆激肽的双重抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
  • Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
    申请人:——
    公开号:US20030139431A1
    公开(公告)日:2003-07-24
    This invention provides compounds having the structure: 1 wherein X=CH, C(CH 3 ) or N; each of R 1 , R 2 , R 3 , R 4 and R 5 is independently H, C 1 -C 10 straight chained or branched alkyl, C 2 -C 10 straight chained or branched alkenyl, C 2 -C 10 straight chained or branched alkynyl, C 3 -C 10 cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, —CN, —C(═Z)R 6 , —C(═Z)OR 6 , —C(═Z)N(R 6 ) 2 , —N(R 6 )—C(═Z)R 6 , —N(R 6 )—C(═Z)N(R 6 ) 2 , —OC(═Z)R 6 , —C(═Z)OR 6 —OR 6 or —SR 6 ; wherein Z is O or S; and wherein R 6 is C 1 -C 10 straight chained or branched alkyl, aryl, (CH 2 ) n Q, C 2 -C 10 alkenyl, C 3 -C 10 cycloalkyl, C 5 -C 10 cycloalkenyl, wherein Q is OR 7 , SR 7 , N(R 7 ) 2 or aryl, wherein R 7 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, wherein R 2 and R 3 and the carbons to which they are attached form a fused aryl, heteroaryl, C 5 -C 10 cyclic alkyl or heterocyclic alkyl ring; or wherein R 3 and R 4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring; and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R a , where R a is 1) hydroxy, 2) C 1 -C 10 alkoxy, 3) halogen, 4) nitro, 5) amino, 6) CF 3 , or 7) carboxy, and each cycloalkyl group is optionally substituted with a substituent independently selected from R b , where R b is 1) a group selected from R a , 2) C 1 -C 7 alkyl, 3) C 2 -C 7 alkenyl, 4) C 2 -C 7 alkynyl or 5) cyclic C 1 -C 10 alkyl, and each aryl is optionally substituted with R 1 . This invention also provides methods of treating pain, urge incontinence; as well as methods of preparing the compounds.
    这项发明提供了具有以下结构的化合物:其中 X==CH,C(CH3)或N;R1、R2、R3、R4和R5中的每一个独立地是H、C1-C10直链或支链烷基、C2-C10直链或支链烯基、C2-C10直链或支链炔基、C3-C10环烷基、取代或未取代芳基、羟基、卤代醚、硝基、氨基、卤素、—CN、—C(═Z)R6、—C(═Z)OR6、—C(═Z)N(R6)2、—N(R6)—C(═Z)R6、—N(R6)—C(═Z)N(R6)2、—OC(═Z)R6、—C(═Z)OR6—OR6或—SR6;其中 Z 是 O 或 S;且其中 R6 是 C1-C10直链或支链烷基、芳基、(CH2)nQ、C2-C10烯基、C3-C10环烷基、C5-C10环烯基,其中 Q 是OR7、SR7、N(R7)2或芳基,其中 R7 是H、烷基、烯基、炔基、环烷基、环烯基、芳基,其中 R2、R3和它们连接的碳形成融合芳基、杂芳基、C5-C10环烷基或杂环烷基环;或其中 R3、R4和它们连接的碳形成融合芳基、杂芳基、环烷基或杂环烷基环;以及每个烷基、烯基、炔基和烷氧基组分可以选择性地取代一个从 Ra 中独立选择的取代基,其中 Ra 是 1) 羟基,2) C1-C10烷氧基,3) 卤素,4) 硝基,5) 氨基,6) CF3,或 7) 羧基,每个环烷基组分可以选择性地取代一个从 Rb 中独立选择的取代基,其中 Rb 是 1) 从 Ra 中选择的一组,2) C1-C7烷基,3) C2-C7烯基,4) C2-C7炔基或 5) 环状 C1-C10 烷基,每个芳基可以选择性地取代为 R1。这项发明还提供了治疗疼痛、尿急失禁的方法;以及制备这些化合物的方法。
  • SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS
    申请人:Corte James R.
    公开号:US20090181983A1
    公开(公告)日:2009-07-16
    The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, R 3 and R 11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    本发明提供了式(I)的化合物:或其立体异构体,互变异构体,药学上可接受的盐或溶剂形式,其中变量A,B,R3和R11如本文所定义。式(I)的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂;例如凝血酶,因子Xa,因子XIa,因子IXa,因子VIIa和/或血浆卡利肯。具体而言,本发明涉及选择性因子XIa抑制剂或fXIa和血浆卡利肯的双重抑制剂化合物。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
  • N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
    申请人:Genfit
    公开号:US11052092B2
    公开(公告)日:2021-07-06
    The present invention provides e.g. N-[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.
    本发明提供了例如N-[2-(哌啶-1-基)苯基](苯基)甲基}-2-(3-氧代-3,4-二氢-2H-1,4-苯并恶嗪-7-基)乙酰胺衍生物和相关化合物作为ROR-γ调节剂,用于治疗例如自身免疫性疾病、自身免疫相关疾病、炎症性疾病、代谢性疾病、纤维化疾病或胆汁淤积性疾病,例如关节炎和哮喘。
  • COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION
    申请人:Carlson Heather A.
    公开号:US20110105477A1
    公开(公告)日:2011-05-05
    The present invention relates to HIV protease, and methods for inhibiting the function of HIV protease. In particular, present invention provides compounds that inhibit or block the biological activity of HIVp, thereby causing the replication of the HIV virus to be inhibited or to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS. The compounds and formulations also find use in diagnostic and research settings.
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台